Kornimate/medical-research-clean huggingface dataset:
the effect of aromatherapy with thyme oil on disease symptoms, vital signs, hemodynamic parameters in covid-19 patients

Conditions: Patient Engagement

Summary: coronavirus, which is a common infectious disease, is characterized by symptoms such as severe pain, cough, shortness of breath, dizziness, secretion, diarrhea, nausea-vomiting, weakness, runny nose, changes in sense of taste and smell, and loss of appetite. the use of thyme is common for this disease whose standard treatment is still being discussed. however, studies investigating the effectiveness of oregano oil are limited. these few studies in the literature have focused especially on the effects of thyme oil on covid-19 symptoms. this work; it will be done to evaluate the effect of aromatherapy with thyme oil on covid-19 symptoms, vital signs and hemodynamic parameters in covid-19 patients. there is no study in the literature investigating the effects of all these variables.

coronavirus, which is a common infectious disease, is characterized by symptoms such as severe pain, cough, shortness of breath, dizziness, secretion, diarrhea, nausea-vomiting, weakness, runny nose, changes in sense of taste and smell, and loss of appetite. the use of thyme is common for this disease whose standard treatment is still being discussed. however, studies investigating the effectiveness of oregano oil are limited. these few studies in the literature have focused especially on the effects of thyme oil on covid-19 symptoms. this work; it will be done to evaluate the effect of aromatherapy with thyme oil on covid-19 symptoms, vital signs and hemodynamic parameters in covid-19 patients. there is no study in the literature investigating the effects of all these variables. the study will be carried out as a randomized controlled experimental study. it will be carried out in batman training and research hospital covid-19 service between january 2022 and december 2022. the sample of the study will consist of a total of 140 patients (experimental group = 70 control group = 70) randomized to the experimental and control groups. in data collection, "demographic characteristics form", "covid-19 symptom form", "hemodynamic parameters and vital signs follow-up form" and "visual comparison scale (vas)" will be used. kolmogorov smirnov normality test will be used for normal distribution in the analysis of the data. using anova, ancova, student t test and paired t test in the analysis of normally distributed data; fridman test, kruskal wallis and man withney u test are planned to be used in the analysis of data that is not normally distributed.

Eligibility criteria:
inclusion criteria: * pcr test positive * being in the covid-19 service * involvement in the lung as a result of computed tomography between 50-80% to be * the day of admission to the covid 19 service (1. day) sickareceipt of exclusion criteria: * having a pregnancy status * be under the age of 18 * unwillingness to participate in the study * patients who will be transferred to the intensive care unit will be excluded from the study.

Keywords: coronavirus covid-19 aromatherapy thyme oil thymus vulgaris
transcutaneous tibial nerve stimulation in patients with neurogenic overactive bladder after stroke

Conditions: Urinary Bladder, Overactive

Summary: the investigators conducted a prospective, randomized, double-blind, placebo-controlled study based on the placebo technique to evaluate the efficacy of ttns versus placebo in patients with oab after stroke. the main questions aimed to be answered are: what are the effects of trans tibial nerve stimulation (ttns) on incontinence-related clinical parameters and quality of life in patients with overactive bladder (oab) after stroke compared to the placebo group? participants (n:22) with post-stroke aam who meet the exclusion and inclusion criteria will be divided into 2 groups using a randomization table. the first group will receive ttns (n:11) and the second group will receive placebo ttns (n:11). measurements will be performed twice in total, before treatment and at the end of treatment (4th week).


Eligibility criteria:
inclusion criteria: * patients aged 40 and above with stable ischemic or hemorrhagic stroke. * patients with neurogenic detrusor overactivity symptoms accompanied by urinary incontinence complaints and a urinary frequency of 9 or more. * patients diagnosed with detrusor overactivity on urodynamic evaluation. * patients with hemiplegia lasting between 30 days and 1 year. * ability to understand procedures, benefits, and potential side effects. * patients scoring 22 or above on the mini mental test. exclusion criteria: * patients with post-stroke neurogenic detrusor overactivity receiving or previously received pharmacological treatment. * patients using intermittent catheterization or permanent catheterization as a bladder emptying method. * patients with a history of urinary incontinence and/or urinary retention before stroke. * history of past urogynecological surgery. * presence of urinary tract infection, bladder tumor, or cardiac pacemaker. * significant fluid infusion requirement affecting urination or use of medication affecting bladder function. * patients who have received botulinum toxin injection for post-stroke neurogenic detrusor overactivity. * patients with postvoid residual volume above 150 ml.

Keywords: overactive bladder after stroke transcutaneous tibial nerve stimulation urinary incontinence
a study of nab-paclitaxel and gemcitabine with or without olaratumab (ly3012207) in participants with metastatic pancreatic cancer

Conditions: Metastatic Pancreatic Cancer

Summary: the purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.


Eligibility criteria:
inclusion criteria: * histological or cytological diagnosis of adenocarcinoma of the exocrine pancreas that is metastatic (stage iv) and not amenable to resection with curative intent. * if present, clinically significant or symptomatic amounts of ascites should be drained prior to day 1. * have had no prior systemic treatment for metastatic disease. prior adjuvant or neo-adjuvant chemotherapy or radiochemotherapy (other than nab-paclitaxel) is allowed if completed ≥3 months prior to enrollment and no lingering toxicities are present. * prior radiation therapy for treatment of cancer is allowed to \<25% of the bone marrow. * phase 2: archival tumor tissue or be willing to provide a pre-treatment biopsy. * measurable or nonmeasurable but evaluable disease as defined by the response evaluation criteria in solid tumors (recist 1.1). * eastern cooperative oncology group (ecog) performance status of 0 to 1. * discontinued all previous treatments for cancer ≥4 weeks prior. * adequate organ function. * life expectancy of at least 3 months. exclusion criteria: * serious concomitant systemic disorder. * have received first line treatment for metastatic pancreatic cancer. * received prior treatment with nab-paclitaxel. * have known central nervous system malignancy or metastasis. * current hematologic malignancies. * participated within the last 30 days in a clinical trial involving an investigational product. * women with a positive pregnancy test or lactating. * have endocrine pancreatic tumors or ampullary cancer. * currently enrolled in another clinical trial. * have a known additional malignancy that is progressing or required active treatment within the past 1 year. * known allergy to nab-paclitaxel or gemcitabine or any ingredient of study drug formulations. * are taking certain anti-coagulant medications such as warfarin and are unable to be switched to other similar medicines.
efficacy and safety of the elios laser in combined cataract and glaucoma surgery

Conditions: Glaucoma

Summary: glaucoma is an irreversible optic neuropathy. it is the second most common cause of blindness worldwide. glaucoma can be treated with topical medications (eye drops), laser or surgery. traditional surgery is invasive and has a high complication rate (hypotonia, endophthalmitis, cataracts, etc.). as a result, several types of micro-invasive surgery (migs) have been developed to reduce the risks of surgery while maintaining their effectiveness in lowering intraocular pressure (iop). the elios laser system is the only ophthalmological excimer laser designed for the surgical treatment of glaucoma. the aim of the procedure is to ablate the trabecular meshwork and inner wall of schlemm´s canal ab interno, with the creation of 10 microchannels of 210 um in the trabeculum using the elios laser with a wavelength of 308 nm, in order to improve trabecular outflow to achieve a reduction in iop. the elios laser is an example of microinvasive glaucoma surgery (migs) with published results demonstrating efficacy and safety. the elios laser is already in use in france (amm / ce mark achieved). its use as part of a prospective interventional study will enable us to collect data in order to treat patients more effectively and improve the quality of care provided to glaucoma patients.


Eligibility criteria:
inclusion criteria: * patients ≥ 18 years of age who agree to take part in the study and have signed an informed consent form * visually significant cataract with indication for surgery * primary open-angle glaucoma, or secondary open-angle glaucoma (pseudoexfoliative glaucoma or pigmentary glaucoma) with indication for cataract surgery. * open iridocorneal angle (shaffer classification grade 2-4) * early to moderate glaucoma (advanced glaucoma, with md from vfs worse than -12db, will be excluded) exclusion criteria: * presence of severe systemic pathologies 2024-a01891-46_protocol_v6_21112024_elios page 20 / 58 * pregnant or breastfeeding women * \<18 years of age * presence of other ophthalmological pathologies (except cataracts), and exclusion of severe dry eye. * history of intraocular surgery, trauma, or conjunctival scarring in the quadrant intended for surgery * visual acuity worse than "counting fingers". * closure of the iridocorneal angle (and angle-closure glaucoma), angle-closure glaucoma secondary to iridocorneal synechiae, neovascular glaucoma or neovascularization of the iris. * normal-pressure glaucoma * pachymetry \ 620 μm * glaucomatous visual field with mean deviation worse than ≤-12 db * iop \> 35 mmhg * autoimmune disorder, especially collagenosis * patient under protective supervision * patient not covered by a social security scheme

Keywords: glaucoma elios laser micro-invasive surgery goniotomy
mirvaso® gel and dysport® for erythema and flushing of rosacea

Conditions: Erythema and Flushing Associated With Rosacea

Summary: to evaluate the safety and efficacy of mirvaso® gel and dysport® for erythema and flushing of rosacea.

to assess the improvement of facial erythema and flushing while using mirvaso® and dysport® treatments based on the clinician's and patient's assessments using a verified 5-point grading scale

Eligibility criteria:
inclusion criteria: 1. male or female 2. 18 years of age or older 3. clinical diagnosis of rosacea 4. moderate to severe persistent facial erythema associated with rosacea at baseline, as determined by: a grade of greater than or equal to 3 on the 5 point grading scale1 (figure 1) 5. no known medical conditions that may interfere with study participation 6. willingness to not use any products on their face for the duration of the study 7. read, understand, and sign informed consent forms 8. willingness to sign photography release form 9. willing and able to comply with all follow-up requirements 10. willingness to undergo treatment using mirvaso® gel and dysport® exclusion criteria: 1. any significant skin disease at treatment area 2. any medical condition which could interfere with the treatment 3. inability or unwillingness to follow the treatment schedule 4. inability or unwillingness to sign the informed consent 5. pregnant or lactating 6. allergy to cow's milk protein 7. previous or current use of mirvaso® gel 8. known hypersensitivity to dysport® , mirvaso® gel or any of their ingredients 9. previous dysport® treatment 6 months prior to the screening visit
transcranial direct current stimulation for pain treatment in gulf war illness.

Conditions: Gulf War Syndrome

Summary: the goal of this study is to investigate long-term modulation of pain pathways leading to a suppression of pain symptoms in gulf war illness patients by applying transcranial direct current stimulation.

gulf war illness is a chronic and multisymptomatic disorder affecting returning military veterans of the 1990-1991 gulf war. pain is a major complaint of gulf war illness patients and is a leading cause of disability in veterans diagnosed with musculoskeletal ailments including joint and muscle pain, muscle fatigue, difficulty with lifting objects, and extremity paresthesia's. as a result, the target of the present study is the treatment of the pain symptoms, as this is detectable across all gulf war illness case classification systems. transcranial direct current stimulation (tdcs) is a non-invasive and painless electrical stimulation technique that has already demonstrated to improve pain symptoms in other patient populations, e.g. fibromyalgia patients. to investigate whether we can improve pain symptoms in gwi patients with pain complaints, we will compare behavioral (questionnaires) and electrophysiological (electroencephalography) measures before and immediately after 10 sessions of tdcs and on several follow up sessions after the last tdcs from 2 groups.

Eligibility criteria:
inclusion criteria: 1. male and female us military veterans serving during the 1990-1991 gulf war. 2. men and women between the ages of 18 and 50 years old during service in the gulf war (born between 1940 and 1973). 3. english speakers. exclusion criteria: 1. non-english speakers. 2. history of a neurological disorder, including dementia of any type, moderate to severe traumatic brain injury (tbi), brain tumors, present or past drug abuse, stroke, blood vessel abnormalities in the brain, parkinson's disease, huntington's disease, or multiple sclerosis. traumatic brain injury will be screened by history. 3. no subjects will be enrolled who are cognitively or clinically incompetent to give informed consent. 4. subjects cannot be taking medications that include: amphetamines, l-dopa, carbamazepine, sulpiride, pergolide, lorazepam, rivastigmine, dextromethorphan, d-cycloserine, flunarizine, ropinirole,or citalopram. 5. subjects with cardiac pacemakers, implanted medication pumps of any sort, or a history of bad heart disease, a history of seizures and/or family members with a history of seizures, and/or the presence of any metal objects in or near the head which cannot be safely removed for the duration of this study.

Keywords: transcranial direct current stimulation gulf war illness pain modulation
pentostatin followed by peripheral stem cell transplantation in treating patients with advanced kidney cancer

Conditions: Kidney Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining chemotherapy with donor peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. purpose: phase i/ii trial to study the effectiveness of pentostatin followed by peripheral stem cell transplantation in treating patients who have advanced kidney cancer.

objectives: * determine the duration and efficiency of hematopoietic and immunologic engraftment in patients with advanced renal cell carcinoma treated with pentostatin followed by related allogeneic stem cell transplantation. * determine the hematologic and non-hematologic toxic effects of this regimen in these patients. * determine the incidence and severity of graft-versus-host disease in patients treated with this regimen. outline: this is a dose-escalation study of pentostatin. * phase i: patients receive pentostatin iv on days -7, -5, and -3 followed by allogeneic stem cell transplantation on day 0. beginning on day 1, patients receive filgrastim (g-csf) iv over 1 hour or subcutaneously daily until blood counts recover. as graft-versus-host disease prophylaxis, patients receive cyclosporine iv continuously until stem cell engraftment and then orally with gradual tapering. cohorts of 3 to 6 patients receive escalating doses of pentostatin until the maximum tolerated dose (mtd) is determined. the mtd is defined as the dose at which 2 of 6 patients experience dose-limiting toxicity. * phase ii: patients receive treatment as in phase i at the mtd for pentostatin. patients are followed weekly for 60 days and then monthly for 10 months. projected accrual: a total of 24 patients (12 per phase) will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed advanced renal cell cancer * no bone metastases * no cns disease * must have an allogeneic donor available patient characteristics: age: * over 18 performance status: * ecog 0-1 life expectancy: * 3 to 6 months hematopoietic: * hemoglobin at least 10 g/dl * complete blood count normal hepatic: * bilirubin no greater than 3 times upper limit of normal (uln) * transaminases no greater than 4 times uln * no evidence of portal hypertension renal: * creatinine no greater than 2.0 mg/dl * no uncontrolled hypercalcemia cardiovascular: * no new york heart association class 3 or 4 heart disease pulmonary: * dlco at least 40% of predicted other: * no severe functional neurological impairment * hiv negative * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception prior concurrent therapy: biologic therapy: * no more than 1 prior biologic therapy chemotherapy: * no more than 6 months of prior chemotherapy endocrine therapy: * at least 1 year since prior steroids radiotherapy: * not specified surgery: * not specified

Keywords: stage iii renal cell cancer stage iv renal cell cancer recurrent renal cell cancer
effectiveness of video-assisted cardiopulmonary resuscitation

Conditions: Cardiac Arrest

Summary: sudden cardiac arrest is a major public health problem worldwide and it is one of the leading causes of death in industrialized countries. emergency medical services (ems) dispatchers play an important role to recognize cardiac arrest and give help to the lay first responder via telephone cpr (t-cpr) which improves survival rates. the current technology allows the live video connection between the scene and the dispatcher which provides the opportunity for video-assisted cpr (v-cpr) via the bystander smartphone. effectiveness of v-cpr has only been investigated to a limited extent. comparing effectiveness of v-cpr (effectiveness of chest compression, time parameters eg. time to first chest compression) to t-cpr and non-instructed cpr can be useful to implement v-cpr technology.

sudden cardiac arrest is a major public health problem worldwide and it is one of the leading causes of death in industrialized countries. ems dispatchers play an important role to recognize cardiac arrest and give help to the lay first responder via telephone cpr (t-cpr) which improves survival rates. the current technology allows the live video connection between the scene and the dispatcher which provides the opportunity for video-assisted cpr (v-cpr) via the bystander smartphone. effectiveness of v-cpr has only been investigated to a limited extent. comparing effectiveness of v-cpr (quality of chest compressions: depth, rate, hand position), time parameters: time to recognize cardiac arrest, time of check breathing, total no-flow time, to first chest compression) to t-cpr and non-instructed cpr can be useful to implement v-cpr technology.

Eligibility criteria:
inclusion criteria: * healthy volunteer exclusion criteria: * healthcare professionals (paramedics, nurses, etc.) * pregnant women * people with cardio-pulmonary and musculoskeletal diseases or any other impairment that would risk harm for the volunteer while performing cpr for 2 minutes * psychological disabilities
comparison of pharmacodynamics and pharmacokinetics of biphasic insulin aspart 30 and insulin glargine and insulin glulisine therapy in subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe. the aim of this clinical trial is to compare the 24-hour pharmacodynamics/ pharmacokinetics of biphasic insulin aspart 30 (biasp 30) thrice daily treatment with that of a basal-bolus treatment with insulin glargine and insulin glulisine in type 2 diabetic subjects. pharmacodynamics is the glucose-lowering effect of the study medication over the entire observation phase from the time of administration and the efficacy period while the pharmacokinetics is the amount of the study insulin that can be determined in the blood.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus for 12 months or longer * body mass index (bmi): 25.0-40.0 kg/m2, both inclusive * hba1c between 7.0 and 10.5% at screening * insulin treatment for at least 3 months prior to screening with a total daily dose of 0.6 and 0.9 u/kg body weight exclusion criteria: * use of any oral antidiabetic agent within the past 2 months * cardiac disease: nyha class iii or iv chronic heart failure (chf), unstable angina, and/or any myocardial infarction (treated or untreated) within 6 months prior to screening * hepatic insufficiency (alanine aminotransferase (alt) or aspartate aminotransferase (ast) equal to or greater than 2 times the central laboratory's upper reference limit) * renal insufficiency (serum creatinine equal to or greater than 1.6 mg/dl for males; equal to or greater than 1.4 mg/dl for females) * recurrent hypoglycaemia * anaemia (haemoglobin less than 13.0 mg/dl in males and less than 12.0 mg/dl in females; who-criteria) * use of concomitant medications (prescribed or non-prescribed and other than insulin) which may alter glucose metabolism including but not limited to: systemic or inhaled glucocorticoids, anabolic steroids, non-selective beta-blockers
spinal anesthesia using ultrasound assistance versus conventional palpation in morbidly obese patients

Conditions: Spinal Anesthesia; Ultrasound Assistance; Obesity, Morbid

Summary: the aim of this study is to compare the paramedian approach for spinal anesthesia using ultrasound assistance (usas) versus conventional palpation in morbidly obese patients undergoing elective surgeries.

performing spinal anesthesia using a conventional approach can be considerably challenging in obese patients. multiple needle attempts may lead to a higher incidence of complications (e.g., postdural puncture headache, paresthesia, hematoma, and infection) and increase patient discomfort and dissatisfaction. therefore, novel techniques are needed to improve the success rate of spinal anesthesia for such patients. there are two puncture approaches for spinal anesthesia: median approach puncture and paramedian approach puncture. early studies have noted that the success rate of paramedian approach puncture was higher than that of median approach puncture and that it is associated with fewer complications and postoperative complications. a paramedian approach has been shown to improve the success rate of spinal anesthesia, especially in patients who are unable to sit up or those with a degenerative spine condition. the use of ultrasound has been suggested to increase the efficacy of spinal anesthesia. recently, ultrasound has emerged as a way to facilitate lumbar neuraxial blocks, namely, the ultrasound assistance (usas) technique. the ultrasound assistance technique is beneficial for lumbar neuraxial anesthesia, improving technique performance by providing reliable anatomical information.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * both sexes * body mass index (bmi) ≥ 40 kg/m2 * patients undergoing elective surgeries exclusion criteria: * rejection of spinal anesthesia * history of spinal deformity or spinal surgery * contraindications to spinal anesthesia (infection of the puncture site, coagulation dysfunction, allergy to local anesthesia, insufficient blood volume or abnormal spinal anatomy).